TYVA HIGGINS: Open Payments
NPI 1891365607 · MEXICO, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,826 in 109 payments from 13 companies in 2025. Trend: 2023 $1,535 · 2024 $846 · 2025 $1,826
Food & beverage: $1,709Education: $117
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 19 | $355 |
| Teva Pharmaceuticals USA, Inc. | 14 | $245 |
| Axsome Therapeutics, Inc. | 12 | $237 |
| E.R. Squibb & Sons, L.L.C. | 13 | $214 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $188 |
| Otsuka America Pharmaceutical, Inc. | 12 | $160 |
| ABBVIE INC. | 6 | $107 |
| Janssen Pharmaceuticals, Inc | 4 | $74 |
| Alkermes, Inc. | 4 | $72 |
| Vanda Pharmaceuticals Inc. | 4 | $63 |
Products named: INGREZZA, Auvelity, COBENFY, CAPLYTA, REXULTI, VRAYLAR, AUSTEDO XR, ABILIFY MAINTENA.
Industry payments across MO — which companies pay providers there.
